Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) on January 12 and set a price target of ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.55, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 0.44%, the current ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.iXkfgCgn.js ...

Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, ...

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective raised by Piper Sandler from $52.00 to $53.00 in a report published on Friday,Benzinga reports. They currently have a neutral ...

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance ...

Wells Fargo has recently reduced Halozyme Therapeutics, Inc. (HALO) stock to Equal Weight rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 19, 2024, JP Morgan had ...